For education only · Not medical advice
← All articles
November 2026 Weight & Metabolic 6 min read

Oral semaglutide: how Rybelsus and the oral Wegovy tablet differ from the injection

Semaglutide was designed as a weekly injection, and getting the same peptide to survive the stomach required an absorption enhancer, a ten-fold larger dose and a set of administration rules that decide whether the drug works at all, which is why the oral versions are worth understanding as their own products rather than as a pill form of the shot.

The short answer

  • Oral semaglutide is the same molecule as the injection, co-formulated with an absorption enhancer called SNAC.
  • Bioavailability is only about 1 to 2%, which is why oral doses are roughly ten times larger than subcutaneous ones.
  • There are three distinct tablet products, and they are not interchangeable milligram for milligram.
  • The 25 mg daily tablet for chronic weight management is FDA-approved but not authorised in Canada as of September 2026. Canadian oral semaglutide is authorised for type 2 diabetes only.
  • The administration rules are not optional: on waking, empty stomach, up to 120 mL of plain water, then wait at least 30 minutes before food, drink or other oral medicines.

Why a tablet needed re-engineering

Semaglutide is a 31-amino-acid analogue of human GLP-1. Two structural tricks give it its weekly injectable profile: an alpha-aminoisobutyric acid substitution at position 8 that resists DPP-4 cleavage, and a C18 fatty diacid on Lys26 that binds albumin. Together they stretch the half-life to about a week.

Neither trick helps a peptide survive a stomach. The oral tablets therefore include SNAC, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, which transiently raises local gastric pH and enables transcellular absorption across the stomach wall.

It works, but inefficiently. Absolute bioavailability is about 1 to 2% for the 25 mg tablet and the newer 1.5/4/9 mg tablets, and roughly 0.4 to 1% for the original Rybelsus formulation, against 89% for the subcutaneous route. Tmax is about an hour for the tablets versus 1 to 3 days for the injection. The half-life is about a week either way, and semaglutide remains in circulation for about 5 to 7 weeks after the last dose.

The convergence point is the one number worth remembering: 25 mg orally produces steady-state concentrations of about 77 nmol/L, close to the roughly 75 nmol/L produced by 2.4 mg weekly subcutaneously. Ten times the dose, same exposure.

The three tablet products, and why they are not swappable

This is where most confusion starts.

Rybelsus, 3 / 7 / 14 mg. The original oral formulation, approved for type 2 diabetes glycaemic control. The US label runs 3 mg for 30 days, then 7 mg, then 14 mg if needed. Rybelsus also carries a cardiovascular indication in the US following the SOUL trial, approved October 2025.

The newer tablet formulation, 1.5 / 4 / 9 mg. Marketed in the US as Ozempic tablets. The two sets are not interchangeable milligram for milligram: 1.5, 4 and 9 mg of the new tablets give roughly the same exposure as 3, 7 and 14 mg of Rybelsus. Canada markets both sets of Rybelsus strengths, with the 1.5/4/9 mg tablets marketed from March 2026.

Wegovy tablets, 25 mg daily. Approved by FDA on 22 December 2025 and launched in January 2026, for chronic weight management and for cardiovascular risk reduction. The label escalation runs 1.5 mg daily for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg daily as maintenance.

A prescription that says “oral semaglutide 14 mg” and one that says “oral semaglutide 9 mg” may be describing near-identical exposure. Anyone reading across the three products needs to know which formulation they are looking at.

The administration rules

For the Wegovy tablet the label is specific: take on waking, on an empty stomach, with no more than 120 mL (4 oz) of plain water, and wait at least 30 minutes before any food, drink or other oral medicine.

That window is not a nicety. SNAC-mediated absorption happens in a narrow gastric moment, and food or fluid in the stomach changes it. It also has a knock-on effect that is easy to underestimate: it pushes every other morning medicine back by half an hour.

Switching between routes has its own rules. Going from the 2.4 mg weekly injection to 25 mg tablets, the label has the first tablet one week after the last injection. Going the other way, from 25 mg tablets to the 2.4 mg injection, the first injection is the next day. Those are not symmetrical, and the asymmetry follows from the week-long half-life.

Delayed gastric emptying also matters for co-medication generally. Narrow-therapeutic-index oral drugs such as warfarin deserve monitoring, and the tablet has one specific documented interaction: levothyroxine exposure rose 33% when it was taken alongside semaglutide tablets, so the Rybelsus label calls for thyroid monitoring. The strict administration rules also constrain when any other morning medicine can be taken.

What the oral trials showed

Weight. OASIS 4 tested oral semaglutide 25 mg daily for 64 weeks and reported weight change of -13.6% versus -2.2% with placebo. An earlier trial, OASIS 1, used 50 mg daily over 68 weeks. For cross-route context, the subcutaneous STEP 1 trial reported -14.9% versus -2.4% at 68 weeks with 2.4 mg weekly, and the higher 7.2 mg weekly dose in STEP UP reported -18.7% versus -15.6% for 2.4 mg and -3.9% for placebo at 72 weeks.

So oral 25 mg lands in roughly the same territory as 2.4 mg weekly injection, which is what the pharmacokinetics predicted, and below the 7.2 mg weekly dose.

Cardiovascular outcomes. SOUL tested oral semaglutide 14 mg in high-risk type 2 diabetes and reported a major adverse cardiovascular event hazard ratio of 0.86 over about four years. PIONEER 6, the earlier oral cardiovascular safety trial, was a noninferiority result.

A negative result worth knowing. The EVOKE and EVOKE+ trials tested oral semaglutide 14 mg daily in early Alzheimer’s disease over two years and found no clinical benefit. Large, well-run, negative.

Evidence tier for oral semaglutide is therefore Approved for type 2 diabetes glycaemic control, for cardiovascular risk reduction in the populations studied, and, in the US, for chronic weight management at 25 mg daily. It is Human trials, negative for early Alzheimer’s disease.

The Canadian position, as of September 2026

This is the part most easily got wrong by readers following US coverage.

Oral semaglutide 25 mg for weight has no Canadian Drug Product Database record. Canadian oral semaglutide, Rybelsus, is authorised for type 2 diabetes only. The injectable Wegovy is authorised in Canada for chronic weight management in adults and in adolescents aged 12 to 17 weighing over 60 kg, and separately for reducing the risk of non-fatal myocardial infarction in established cardiovascular disease with BMI 27 or above, which is a narrower cardiovascular claim than the US label carries.

Canada also became the first G7 country to approve a generic semaglutide, on 28 April 2026. Those generics are injections. As of September 2026, of the Canadian generics only Sevmia held authorisation for chronic weight management.

Two other pending items, per the manufacturer’s Q2 2026 filing: an FDA decision on the 25 mg oral tablet for type 2 diabetes was expected in Q4 2026, and a decision on MASH data for the oral product in Q1 2027. Neither was approved as of September 2026.

Safety, which is the class profile

Switching route does not switch the safety profile. Gastrointestinal effects dominate: nausea, diarrhoea, vomiting, constipation and abdominal pain, mostly during escalation. Label warnings include acute pancreatitis, acute gallbladder disease, hypoglycaemia in combination with insulin or a sulfonylurea, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity and anaphylaxis, diabetic retinopathy complications in type 2 diabetes, heart-rate increase, and pulmonary aspiration during anaesthesia or deep sedation. There is a boxed warning for rodent thyroid C-cell tumours, and a contraindication for personal or family history of medullary thyroid carcinoma or MEN 2.

Two points specific to the tablet. Breastfeeding is not recommended with the Wegovy tablets because of SNAC, whereas the injection has limited rather than negative data. And because the half-life is about a week regardless of route, the label advice to stop at least two months before a planned pregnancy applies to tablets too.

For the wider molecule and route comparisons, see the semaglutide profile, the GLP-1 overview, and the three-way comparison.

The bottom line

Oral semaglutide is the same peptide delivered by a much less efficient route, which is why the doses are ten-fold larger and the morning rules exist. At 25 mg daily the exposure and the weight-trial results sit close to 2.4 mg weekly by injection, and the oral 14 mg dose carries its own cardiovascular outcome data from SOUL. The two facts most often missed are that the three tablet formulations cannot be swapped milligram for milligram, and that the 25 mg weight-management tablet is not authorised in Canada as of September 2026.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

Questions

What is oral semaglutide?

Oral semaglutide is the same molecule as the weekly semaglutide product, co-formulated with an absorption enhancer called SNAC so that it survives the stomach. Its bioavailability is only about 1 to 2%.

Is oral semaglutide approved in Canada?

Canadian oral semaglutide, Rybelsus, is authorised for type 2 diabetes only. The Wegovy tablet for chronic weight management is FDA-approved but has no Canadian Drug Product Database record and is not authorised in Canada as of September 2026.

Can the three oral semaglutide tablet products be swapped for each other?

No. There are three distinct tablet products, Rybelsus, the newer Ozempic tablets and the Wegovy tablets, and they are not interchangeable milligram for milligram.

Peptides 101SemaglutideGLP-1
For education only · Not medical advice